Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified TEAM conditioning before autologous HSCT in high-risk CNS non-Hodgkin lymphoma
ChiCTR2600121178Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thiotepa, etoposide, cytarabine and melphalan in non-Hodgkin lymphoma (NHL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Progression-free survival at 2 years, Overall survival and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
thiotepaetoposidecytarabinemelphalan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR2600121178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121178.